bioRxiv Science⌕ Search

Biology subjects

Bartels-Burgahn, F.

Publications and source records attributed to Bartels-Burgahn, F..

1 recordsLinked to original sources

Structural principles of B-cell antigen receptor assembly

The B-cell antigen receptor (BCR) is composed of a membrane-bound immunoglobulin (mIg) of class M, D, G, A or E for antigen recognition and a disulfide-linked heterodimer between Ig and Ig{beta} (Ig/{beta}, also known as CD79A and CD79B) that functions as the signalling entity. The organizing principle of BCR assembly remains elusive. Here we report the cryo-electron microscopy structures of the intact IgM class BCR at 8.2 [A] resolution and its Fab-deleted form (IgM BCR{Delta}Fab) at 3.6 [A] resolution. At the ectodomain (ECD), Ig and Ig{beta} position their respective Ig folds roughly in parallel with an approximate 2-fold symmetry, which is distinct from structures of Ig{beta}/{beta} homodimers. Unlike previous predictions, the BCR structure displays an asymmetric arrangement, in which the Ig/{beta} ECD heterodimer mainly uses Ig to associate with C{micro}3-C{micro}4 domains of one heavy chain ({micro}HC) while leaving the other heavy chain ({micro}HC) empty. The transmembrane domain (TMD) helices of the two {micro}HCs also deviate from the 2-fold symmetry of the C{micro}3-C{micro}4 domain dimer and form together with the TMD helices of the Ig/{beta} heterodimer a tight 4-helix bundle. The asymmetry at the TMD helices prevents the recruitment of two Ig/{beta} heterodimers. Surprisingly, the connecting peptides (CPs) between the ECD and TMD are braided together through striking charge complementarity, resulting in intervening of the CP of {micro}HC in between those of Ig and Ig{beta} and crossover of the TMD relative to ECD for the Ig/{beta} heterodimer, to guide the TMD assembly. Interfacial analyses suggest that the IgM BCR structure we present here may represent a general organizational architecture of all BCR classes. Our studies thus provide a structural platform for understanding B-cell signalling and for designing rational therapies against BCR-mediated diseases.

immunology↗